These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11264471)

  • 1. Drug treatment effects on disease progression.
    Chan PL; Holford NH
    Annu Rev Pharmacol Toxicol; 2001; 41():625-59. PubMed ID: 11264471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of Alzheimer disease: symptomatic or neuroprotective?
    Giacobini E
    J Neural Transm Suppl; 1994; 43():211-7. PubMed ID: 7884402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management of Parkinson's disease.
    Salawu F; Olokoba A; Danburam A
    Ann Afr Med; 2010; 9(2):55-61. PubMed ID: 20587924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slowing the progression of Alzheimer disease: methodologic issues.
    Leber P
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 5():S10-21; discussion S37-9. PubMed ID: 9348423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.
    Ploeger BA; Holford NH
    Pharm Stat; 2009; 8(3):225-38. PubMed ID: 19025967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current pharmacotherapy of Parkinson's disease].
    Takáts A
    Orv Hetil; 2000 Mar; 141(10):483-8. PubMed ID: 10750400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O
    Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of disease progression and dropout for Alzheimer's disease.
    William-Faltaos D; Chen Y; Wang Y; Gobburu J; Zhu H
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):120-31. PubMed ID: 23211395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Realistic expectations for treatment success in Alzheimer's disease.
    Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
    J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of clinical trials of gene therapy in Parkinson disease.
    Lewis TB; Standaert DG
    Exp Neurol; 2008 Jan; 209(1):41-7. PubMed ID: 17920590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases].
    Maloteaux JM
    Bull Mem Acad R Med Belg; 1996; 151(10-11):429-32; discussion 432-4. PubMed ID: 9491620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease system analysis: basic disease progression models in degenerative disease.
    Post TM; Freijer JI; DeJongh J; Danhof M
    Pharm Res; 2005 Jul; 22(7):1038-49. PubMed ID: 16028004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic.
    Horstink MW; van Engelen BG
    Arch Neurol; 2003 Aug; 60(8):1170-2; author reply 1172-3. PubMed ID: 12925381
    [No Abstract]   [Full Text] [Related]  

  • 16. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Natural progression of Alzheimer's disease (AD): a perspective on possible therapies for advanced AD].
    Yanagisawa K
    Rinsho Shinkeigaku; 2004 Nov; 44(11):921-3. PubMed ID: 15651332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Insight: new drugs in development for Parkinson's disease.
    Colosimo C; Fabbrini G; Berardelli A
    Nat Clin Pract Neurol; 2006 Nov; 2(11):600-10. PubMed ID: 17057747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term progression of Alzheimer's disease in patients under antidementia drugs.
    Gillette-Guyonnet S; Andrieu S; Nourhashemi F; Gardette V; Coley N; Cantet C; Gauthier S; Ousset PJ; Vellas B;
    Alzheimers Dement; 2011 Nov; 7(6):579-92. PubMed ID: 22055975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for?
    Martínez-Banaclocha MA
    Med Hypotheses; 2012 Jul; 79(1):8-12. PubMed ID: 22546753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.